Sonib 200 mg (Tablet)
Unit Price: ৳ 250.00 (4 x 7: ৳ 7,000.00)
Strip Price: ৳ 1,750.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sorafenib tosylate |
| Company | Drug international ltd |
Indications
- Unresectable Hepatocellular Carcinoma (HCC)
- Advanced Renal Cell Carcinoma (RCC)
Pharmacology
Kinase inhibitor, decreases tumor cell proliferation, inhibits multiple intracellular and cell surface kinases, involved in tumor cell signaling, angiogenesis, and apoptosis
Dosage & Administration
- Recommended daily dose of 400 mg tablets taken twice daily without food
- Temporary interruption and/or dose reduction may be required for management of adverse drug reactions
- No dose adjustment required based on patient age, gender, or body weight
- Missed dose instructions provided
Interaction
- Contraindicated in combination with carboplatin and paclitaxel for squamous cell lung cancer
- Systemic exposure to substrates of UGT1A1 and UGT1A9 may increase when co-administered
- Caution recommended with concomitant use of Docetaxel, Doxorubicin, Fluorouracil, CYP2B6, CYP2C8 substrates, CYP3A4 inducers, CYP3A4 inhibitors, CYP isoform substrates, P-glycoprotein substrates, Neomycin
- No effect on the pharmacokinetics of gemcitabine or oxaliplatin
Contraindications
- Known severe hypersensitivity to Sorafenib or any other component
- Contraindicated in combination with carboplatin and paclitaxel for squamous cell lung cancer
Side Effects
- Cardiac ischemia, infarction
- Hemorrhage
- Hypertension
- Hand-foot skin reaction and rash
- Gastrointestinal perforation
- Wound healing complications
Pregnancy & Lactation
- May cause fetal harm when administered to a pregnant woman
- Women of childbearing potential advised to avoid becoming pregnant while on Sorafenib
- Not known whether excreted in human milk
Precautions & Warnings
- Consideration for discontinuation in case of cardiac ischemia, infarction
- Increased risk of bleeding
- Risk of hypertension
- Dermatologic toxicities
- Gastrointestinal perforation
- Regular monitoring for patients taking concomitant warfarin
- Use in combination with Carboplatin and Paclitaxel in Non-small Cell Lung Cancer
- Interactions with UGT1A1 Substrates, Docetaxel, Doxorubicin
- Hepatic impairment effects, Neomycin co-administration effects
Use in Special Populations
- Safety and effectiveness not studied in pediatric patients
- No differences in safety or efficacy observed between older and younger patients
- No dose adjustment required for patients with renal impairment
- Lower AUC in mild and moderate hepatic impairment, not studied in severe hepatic impairment
Overdose Effects
- No specific treatment for overdose
- Highest clinically studied dose is 800 mg twice daily
- Adverse reactions observed at this dose were primarily diarrhea and dermatologic
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
- Store at room temperature below 30°C
- Dispense in original bottle